John B.A.G. Haanen

97.8k citations

429 papers · 23.8k indexed · 18 hit papers · h-index 72

Oncology top 0.05%
Immunology top 0.05%
Molecular Biology top 0.5%
Pulmonary and Respiratory Medicine top 0.2%
Cancer Research top 0.5%

Co-authors: Ton N. Schumacher Christian U. Blank Caroline Robert James Larkin Solange Peters Karin Jordan Franck Carbonnel Hergen Spits
Topics: Cancer Immunotherapy and Biomarkers (170 papers)CAR-T cell therapy research (160 papers)Immunotherapy and Immune Responses (138 papers)
Cited by: Immunology Oncology Pulmonary and Respiratory Medicine
Journals: Nature Science New England Journal of Medicine
Partner nations: Netherlands United States United Kingdom

In The Last Decade

John B.A.G. Haanen

417 papers receiving 23.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 1.7k citations John B.A.G. Haanen, James Larkin et al. Annals of Oncology profile →
Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

1991 1.7k citations John B.A.G. Haanen, Carl G. Figdor et al. profile →
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

2018 659 citations Elisa A. Rozeman, John B.A.G. Haanen et al. profile →
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

2013 624 citations Daisy Philips, John B.A.G. Haanen et al. profile →
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 565 citations John B.A.G. Haanen, James Larkin et al. Annals of Oncology profile →
The “cancer immunogram”

2016 540 citations Christian U. Blank, John B.A.G. Haanen et al. Science profile →
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

2014 527 citations Carsten Linnemann, Els M.E. Verdegaal et al. profile →
Evolving synergistic combinations of targeted immunotherapies to combat cancer

2015 498 citations John B.A.G. Haanen et al. profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Oscar Krijgsman, Paulien Cornelissen‐Steijger et al. profile →
Skin-resident memory CD8 ⁺ T cells trigger a state of tissue-wide pathogen alert

2014 415 citations Silvia Ariotti, Mirjam E. Hoekstra et al. Science profile →
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

2018 373 citations Sander Kelderman, Carsten Linnemann et al. profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations Maartje W. Rohaan, Elisa A. Rozeman et al. Annals of Oncology profile →
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

2022 346 citations John B.A.G. Haanen et al. profile →
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

2018 306 citations John B.A.G. Haanen et al. profile →
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

2021 195 citations Christian U. Blank, John B.A.G. Haanen et al. profile →
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

2022 110 citations Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel et al. profile →
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma

2024 57 citations Ton N. Schumacher, John B.A.G. Haanen et al. profile →
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

2024 40 citations Ton N. Schumacher, John B.A.G. Haanen et al. profile →

Peers

Countries citing papers authored by John B.A.G. Haanen

Since Specialization

Citations

This map shows the geographic impact of John B.A.G. Haanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B.A.G. Haanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B.A.G. Haanen more than expected).

Fields of papers citing papers by John B.A.G. Haanen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B.A.G. Haanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B.A.G. Haanen. The network helps show where John B.A.G. Haanen may publish in the future.

Co-authorship network of co-authors of John B.A.G. Haanen

This figure shows the co-authorship network connecting the top 25 collaborators of John B.A.G. Haanen. A scholar is included among the top collaborators of John B.A.G. Haanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John B.A.G. Haanen. John B.A.G. Haanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial 2025 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown),(unknown),Laura A. Smit,Jan Paul de Boer,Arash Navran,Winan J. van Houdt,Remco de Bree,Lot A. Devriese,John B.A.G. Haanen,Maurits Wondergem,Charlotte L. Zuur,Wouter V. Vogel	0
2	mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy 2024 ·Frontiers in Immunology ·Anastasia Gangaev,Yannick van Sleen,(unknown),(unknown),(unknown),(unknown),Annemarie Boerma,Marieke van der Heiden,Sjoukje F. Oosting,Astrid A.M. van der Veldt,T. Jeroen N. Hiltermann,Corine H. GeurtsvanKessel,Anne‐Marie C. Dingemans,Egbert F. Smit,Elisabeth G.E. de Vries,John B.A.G. Haanen,Pia Kvistborg,Debbie van Baarle	2
3	Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma 2024 ·Annals of Oncology ·Neeraj Agarwal,James Brugarolas,Pooja Ghatalia,S. George,John B.A.G. Haanen,Howard Gurney,Rahul Ravilla,(unknown),Benoit Beuselinck,И. А. Покатаев,Britt B.M. Suelmann,Mark Tuthill,Daniel A. Vaena,Flora Zagouri,Jane Wu,(unknown),(unknown),(unknown),M.B. Atkins	6
4	1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study 2023 ·Annals of Oncology ·(unknown),James Brugarolas,Pooja Ghatalia,S. George,John B.A.G. Haanen,(unknown),Rahul Ravilla,Astrid A.M. van der Veldt,(unknown),И. А. Покатаев,(unknown),Mark Tuthill,Daniel A. Vaena,Flora Zagouri,Jane Wu,(unknown),Rodolfo F. Perini,(unknown),Michael B. Atkins	4
5	Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies 2023 ·Open Forum Infectious Diseases ·Amalia Anastasopoulou,Michael Samarkos,Panagiotis Diamantopoulos,(unknown),Dimitrios C. Ziogas,(unknown),(unknown),John B.A.G. Haanen,Helen Gogas	9
6	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response 2021 ·Proceedings of the National Academy of Sciences ·Anastasia Gangaev,Elisa A. Rozeman,Maartje W. Rohaan,Olga I. Isaeva,Daisy Philips,(unknown),Joost H. van den Berg,Antoni Ribas,Dirk Schadendorf,Bastian Schilling,Ton N. Schumacher,Christian U. Blank,John B.A.G. Haanen,Pia Kvistborg	21
7	Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4 2021 ·Clinical Cancer Research ·Oscar Krijgsman,Kristel Kemper,Julia Boshuizen,David W. Vredevoogd,Elisa A. Rozeman,(unknown),Beaunelle de Bruijn,Paulien Cornelissen‐Steijger,Aida Shahrabi,Martin Del Castillo Velasco‐Herrera,Ji‐Ying Song,Maarten A. Ligtenberg,(unknown),Thomas Kuilman,Petra Ross‐Macdonald,John B.A.G. Haanen,David J. Adams,Christian U. Blank,Daniel S. Peeper	3
8	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial 2021 ·Clinical Cancer Research ·Mehmet Asım Bilen,Brian I. Rini,Martin H. Voss,James Larkin,John B.A.G. Haanen,Laurence Albigès,Lance C. Pagliaro,Éric Voog,Elaine T. Lam,Nikolay Kislov,Bradley A. McGregor,Aly‐Khan A. Lalani,Bo Huang,Alessandra di Pietro,Stan Krulewicz,Paul B. Robbins,Toni K. Choueiri	28
9	BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA 2020 ·Retinal Cases & Brief Reports ·(unknown),(unknown),John B.A.G. Haanen,(unknown)	10
10	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors 2018 ·Cancer Immunology Research ·Emma C. de Moel,Elisa A. Rozeman,Ellen Kapiteijn,Els M.E. Verdegaal,Annette Grummels,Jaap Bakker,T. Huizinga,John B.A.G. Haanen,René E. M. Toes,Diane van der Woude	129
11	Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature 2017 ·Cancer Immunology Research ·Sara M. Melief,Valeria Visconti,Marten Visser,Merel van Diepen,Ellen Kapiteijn,Joost H. van den Berg,John B.A.G. Haanen,Vincent T.H.B.M. Smit,Jan Oosting,Sjoerd H. van der Burg,Els M.E. Verdegaal	24
12	The “cancer immunogram”breakdown → 2016 ·Science ·Christian U. Blank,John B.A.G. Haanen,Antoni Ribas,Ton N. Schumacher	540
13	Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts 2015 ·EMBO Molecular Medicine ·Kristel Kemper,Oscar Krijgsman,Paulien Cornelissen‐Steijger,Aida Shahrabi,Fleur Weeber,Ji‐Ying Song,Thomas Kuilman,Daniël J. Vis,Lodewyk F.A. Wessels,Emile E. Voest,Ton N. Schumacher,Christian U. Blank,David J. Adams,John B.A.G. Haanen,Daniel S. Peeper	103
14	Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response 2014 ·Science Translational Medicine ·Pia Kvistborg,Daisy Philips,Sander Kelderman,Lois Hageman,Christian H. Ottensmeier,Deborah Joseph-Pietras,Marij J.P. Welters,Sjoerd van der Burg,Ellen Kapiteijn,Olivier Michielin,Emanuela Romano,Carsten Linnemann,Daniel E. Speiser,Christian U. Blank,John B.A.G. Haanen,Ton N. Schumacher	288
15	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination 2012 ·Cancer Research ·Erik H.J.G. Aarntzen,I. Jolanda M. de Vries,W. Joost Lesterhuis,Danita H. Schuurhuis,Joannes F.M. Jacobs,Kalijn F. Bol,Gerty Schreibelt,Roel Mus,Johannes H.W. de Wilt,John B.A.G. Haanen,Dirk Schadendorf,Alexandra Croockewit,Willeke A.M. Blokx,Michelle M. van Rossum,William W. Kwok,Gosse J. Adema,Cornelis J.A. Punt,Carl G. Figdor	131
16	Tissue-resident memory CD8 ⁺ T cells continuously patrol skin epithelia to quickly recognize local antigen 2012 ·Proceedings of the National Academy of Sciences ·Silvia Ariotti,Joost B. Beltman,Grzegorz Chodaczek,Mirjam E. Hoekstra,Anna E. van Beek,Raquel Gomez-Eerland,Laila Ritsma,Jacco van Rheenen,Athanasius F. M. Marée,Tomasz Żal,Rob J. de Boer,John B.A.G. Haanen,Ton N. Schumacher	213
17	T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy 2011 ·Clinical Cancer Research ·Esther P.M. Tjin,Debby Konijnenberg,(unknown),Henk Mallo,Jan W. Drijfhout,Kees L. M. C. Franken,Chantal M.A.M. van der Horst,Jan D. Bos,Omgo E. Nieweg,Bin B. R. Kroon,John B.A.G. Haanen,Cornelis J.M. Melief,Florry A. Vyth‐Dreese,Rosalie M. Luiten	32
18	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib 2010 ·Clinical Cancer Research ·Astrid A.M. van der Veldt,Karel Eechoute,Hans Gelderblom,Jourik A. Gietema,Henk‐Jan Guchelaar,Nielka P. van Erp,Alfons J.M. van den Eertwegh,John B.A.G. Haanen,Ron H.J. Mathijssen,Judith A.M. Wessels	127
19	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival 2008 ·Clinical Cancer Research ·Hester van Cruijsen,Astrid A.M. van der Veldt,(unknown),Dinja Oosterhoff,Henk J. Broxterman,Rik J. Scheper,Giuseppe Giaccone,John B.A.G. Haanen,Alfons J.M. van den Eertwegh,Epie Boven,Klaas Hoekman,Tanja D. de Gruijl	111
20	Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer 2008 ·Cancer Research ·Annelies Jorritsma,Adriaan D. Bins,Ton N. Schumacher,John B.A.G. Haanen	5

About John B.A.G. Haanen

John B.A.G. Haanen is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 429 papers that have together received 23.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (170 papers), CAR-T cell therapy research (160 papers) and Immunotherapy and Immune Responses (138 papers). The work is most often cited by research in Immunology (10.8k citations), Oncology (13.9k citations) and Pulmonary and Respiratory Medicine (4.6k citations). John B.A.G. Haanen has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Ton N. Schumacher, Christian U. Blank, Caroline Robert, James Larkin, Solange Peters, Karin Jordan, Franck Carbonnel, Hergen Spits, Keith M. Kerr and Carl G. Figdor. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact